Juventas Therapeutics Closes $12 Million Early Stage Capital Round

Juventas Therapeutics Closes $12 Million Early Stage Capital Round

02/10/2012

Cleveland, OH--Juventas Therapeutics, Inc. has closed a $12 million early stage venture capital investment, the Company announced. The funding will be used to finance two Phase II clinical trials of its lead compound, JVS-100, which recruits stem cells to the site of damaged tissue.

One clinical trial will test safety and effectiveness in patients with heart failure and the second will be on patients with critical limb ischemia.








Find Out More About ESP

Staff Photo

Managing Director Mike Bunker serves as an observer on the Juventas Therapeutics board on behalf of Early Stage Partners